Findings from the Phase III EINSTEIN-Extension study have been presented in the Late Breaking Abstract Session on December 8, 2009 at the 51st Annual Meeting of the American Society of Hematology (ASH) in New Orleans, Louisiana. On this occasion we held a conference call for investors and analysts.
Audio On-demand Recording: Q3 2009 Investor Conference Call
Presentation charts:
PDF / 194 KB 
collectQ3_2009_ConferenceCall_2009-10-27_Redecharts.pdf Q3 2009 Investor Conference Call Presentation Chartspdf
Financial Report as of September 30, 2009 PDF / 1.49 MB collectQB_2009_3_e.pdf Financial Report as of September 30, 2009pdf
Q3 2009 Analyst and Investor Briefing PDF / 73 KB collectBayer_Q3_2009_Analyst_Briefing_01.pdf Q3 2009 Analyst and Investor Briefingpdf
Announcement of the conversion of the no-par value bearer shares to no-par value registered shares PDF / 24 KB collectUmstellungsbekanntmachung_Namensaktie_200909_e.pdf Announcement of the conversion to to no-par value registered sharespdf
Answers to frequently asked questions on registered shares PDF / 52 KB collectQ_A_Namensaktien_englisch_200907.pdf FAQ regarding transition to registered sharespdf
